Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours

NCT04421820 is registered in ClinicalTrials.gov with Bold Therapeutics, Inc. as lead sponsor.

NCT NCT04421820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04421820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours
Lead sponsor
Bold Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 28, 2020
Completion date
September 1, 2026
Enrollment
220 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, colorectal cancer, gastric cancers, pancreatic cancer